Orchestra BioMed to Present at Upcoming Investor Conferences

Rhea-AI Summary

Orchestra BioMed Holdings (Nasdaq: OBIO) has announced its participation in several upcoming investor conferences in early 2025. The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET, and the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, at 8:00 AM ET.

The TD Cowen presentation will be available via webcast, accessible through Orchestra BioMed's website investor section, with replays available for 90 days after the event. Additionally, the company will host one-on-one meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.

Details on the Company’s presence at these conferences are shown below.

Presentations

TD Cowen 45^th Annual Healthcare Conference
Format: Corporate Presentation
Date: March 3, 2025
Time: 2:30 PM ET
Webcast: https://wsw.com/webcast/cowen177/obio/2014707

Barclays 27^th Annual Global Healthcare Conference
Format: Fireside Chat
Date: March 13, 2025
Time: 8:00 AM ET

Live audio webcasts of the TD Cowen presentation can be accessed through the Investors section of the Company’s website at https://investors.orchestrabiomed.com/news-events/events. An archived replay of the webcast will be available on the Company’s website for 90 days following the live event.

The Company will also be hosting 1x1 meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.

About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn .

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:
Jeremy Feffer
LifeSci Advisors
Jfeffer@lifesciadvisors.com

Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
(484) 682-4892
kkirkellis@orchestrabiomed.com

FAQ

When is Orchestra BioMed (OBIO) presenting at the TD Cowen Healthcare Conference in 2025?

Orchestra BioMed will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 2:30 PM ET.

What is the format of OBIO's presentation at the Barclays Healthcare Conference in March 2025?

Orchestra BioMed will participate in a fireside chat format at the Barclays 27th Annual Global Healthcare Conference on March 13, 2025, at 8:00 AM ET.

How long will the OBIO TD Cowen conference webcast be available for replay?

The webcast replay will be available on Orchestra BioMed's website for 90 days following the live event.

Where can investors access Orchestra BioMed's (OBIO) conference webcasts in March 2025?

Investors can access the webcasts through the Investors section of Orchestra BioMed's website at https://investors.orchestrabiomed.com/news-events/events.

Which investor conferences is Orchestra BioMed (OBIO) attending in February-March 2025?

Orchestra BioMed is attending the B. Riley Securities Precision Oncology & RadioPharma Conference (Feb 28), TD Cowen Healthcare Conference (Mar 3), and Barclays Global Healthcare Conference (Mar 13).